Multiple Myeloma Clinical Trial
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Summary
The purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and dexamethasone to placebo in combination with bortezomib and dexamethasone in the treatment of patients with relapsing multiple myeloma who have received one previous therapy.
Full Description
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day to placebo in the treatment of patients with relapsing multiple myeloma who received one previous therapy.
Patients will receive study treatment (masitinib/placebo) with the standard therapy (bortezomib and dexamethazone).
Eligibility Criteria
Inclusion Criteria:
Patient with confirmed multiple myeloma requiring systemic therapy. A
Patient with multiple myeloma relapsing according to the International uniform response criteria for multiple myeloma (IMWG 2009/ revised Bladé criteria) to one previous line of treatment
Patient with measurable progressive disease
Exclusion Criteria:
Patient with peripheral neuropathy Grade >2
Patient with hypersensitivity to bortezomib, boron or dexamethasone
Patient whose disease progressed during or within 60 days of bortezomib treatment or of any other Multiple Myeloma therapy
Patient who received bortezomib within 6 months of randomization to this study
Past discontinuation of bortezomib due to associated grade 3 or higher adverse event
Patient with contra-indication to high dose of steroids (including ongoing active infection, use of live vaccines, virosis such as hepatitis, herpes, varicella, herpes zoster)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Galesburg Illinois, 61401, United States
Bethesda Maryland, 20817, United States
Charlotte North Carolina, 28203, United States
Goldsboro North Carolina, 27534, United States
Milwaukee Wisconsin, 53226, United States
Clermont Ferrand , , France
Corbeil-Essonnes , , France
Le Mans , , France
Limoges , , France
Marseille , , France
Nantes , , France
Paris , , France
Perpignan , , France
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.